TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01934361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lomustine
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
Study: NCT01667900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Study: NCT03563339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-POD
Description: . P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
Study: NCT01378364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single very low dose of AbGn-168H i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single low dose of AbGn-168H i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single medium dose of AbGn-168H i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single high dose of AbGn-168H i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single low dose of AbGn-168H s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: single medium dose of AbGn-168H s.c.
Study: NCT01740830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)
Description: The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)
Description: The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
Study: NCT01392144

Intervention type: PROCEDURE
Intervention: Nitric oxide breath test
Description: Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
Study: NCT04818268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation
Study: NCT02432703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
Study: NCT03730909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: IV infusion
Study: NCT04609098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg [Arakoda]
Description: Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg [Arakoda]
Description: Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg [Arakoda]
Description: Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
Study: NCT02412306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study: NCT02327546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Study: NCT03507842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Cytarabine
Description: High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hign dose Daunorubicin
Description: Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
Study: NCT01126749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study: NCT00976274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: 5 capsules (300 mg/capsule) three times everyday for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 5 capsules three times everyday for 12 weeks
Study: NCT02642601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)
Description: one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
Study: NCT02183675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Telmisartan/Amlodipine fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine/HCTZ
Description: Telmisartan/Amlodipine/HCTZ fixed-dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/HCTZ
Description: Telmisartan/HCTZ fixed-dose combination
Study: NCT03337308

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid + Ezetimibe Fixed-Dose Combination
Description: bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid
Description: bempedoic acid 180 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: ezetimibe 10 mg overencapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Study: NCT01926223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visiting
Study: NCT03858985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)
Description: Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)
Description: Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
Study: NCT02558725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two capsules of aktiferrin F
Description: two capsules of Aktiferrin F or Foliferrin
Study: NCT03305614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided
Study: NCT03559114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline in prophylactic doses administered daily if screening criteria are satisfied.
Study: NCT04738227

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: Low level laser will be applied and post laser results will be seen to assess any improvements.
Study: NCT04326595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical and medical evacuation
Description: surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical and medical evacuation
Description: surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
Study: NCT00569556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case Management
Description: Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
Study: NCT02139761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-tetrahydropalmatine (l-THP)
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Study: NCT01794429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Subcutaneum injection of exenatide once-weekly for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneum injection of placebo once-weekly for 3 months
Study: NCT01241864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study: NCT04703738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue flap + Connective Tissue Graft
Description: The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue flap + Geistlich Fibro-Gide®
Description: The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
Study: NCT03996343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: COMPLETE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: COMPLETE
Study: NCT00267085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Description: CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
Study: NCT01721460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
Study: NCT03173924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Description: Baseline IV followed by PET/CT IMAGING

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.